What is HC Wainwright’s Estimate for MNPR FY2024 Earnings?

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Stock analysts at HC Wainwright boosted their FY2024 earnings estimates for shares of Monopar Therapeutics in a report issued on Monday, November 11th. HC Wainwright analyst S. Lee now anticipates that the company will post earnings per share of ($1.68) for the year, up from their prior forecast of ($2.06). HC Wainwright currently has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($1.48) EPS.

Separately, Rodman & Renshaw assumed coverage on Monopar Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $50.00 price objective for the company.

Monopar Therapeutics Price Performance

MNPR stock opened at $18.23 on Thursday. The stock has a market capitalization of $96.22 million, a PE ratio of -9.25 and a beta of 1.09. Monopar Therapeutics has a fifty-two week low of $1.37 and a fifty-two week high of $38.50. The company has a 50 day moving average price of $8.47 and a 200 day moving average price of $5.10.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09.

Insider Transactions at Monopar Therapeutics

In other news, CFO Karthik Radhakrishnan purchased 1,550 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The shares were acquired at an average cost of $16.25 per share, for a total transaction of $25,187.50. Following the transaction, the chief financial officer now directly owns 1,550 shares of the company’s stock, valued at approximately $25,187.50. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 34.90% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.